Skip to main content

Advertisement

Figure 3 | EJNMMI Research

Figure 3

From: A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT

Figure 3

Tumor/blood ( T / B ) ratios. T/B ratios at 24 h p.i. of (a) 111In-DOTA-trastuzumab Fab and 111In-DOTA-rituximab Fab or (b) 64Cu-DOTA-trastuzumab Fab and 64Cu-DOTA-rituximab Fab, in s.c. human tumor xenografts in athymic mice with increasing HER2 expression. Values shown are mean ± SD (n = 4). The HER2 density (receptors/cell) was 5.4 × 104 (MDA-MB-231), 1.6 × 105 (BT-20), 5.1 × 105 (MDA-MB-361) and 1.2 × 106 (SK-OV-3). Significant differences (P < 0.05) between 111In- or 64Cu-labeled trastuzumab Fab and rituximab Fab are indicated by asterisks. n.d., not determined.

Back to article page